Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 239 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Buffered Saline Clear all

Conditions: Genital Herpes Simplex Type 2
Interventions: VCL-HB01, VCL-HM01, PBS; Biological
Lead sponsor: Vical; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 165 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 7
States / cities: Birmingham, Alabama • Hollywood, Florida • Indianapolis, Indiana + 4 more

Conditions: Influenza
Interventions: Vero cell-derived, trivalent, seasonal influenza vaccine, Placebo: Phosphate-buffered saline; Biological
Lead sponsor: Alachua Government Services, Inc.; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 7,250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 36
States / cities: Tucson, Arizona • Sacramento, California • San Diego, California + 31 more

Conditions: Plasmodium Falciparum Malaria
Interventions: Placebo, EP-1300; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Crohn's Disease
Interventions: Certolizumab pegol; Biological
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 49
States / cities: Birmingham, Alabama • Montgomery, Alabama • La Jolla, California + 46 more

Conditions: Systemic Lupus Erythematosus
Interventions: Epratuzumab, Placebo; Biological · Other
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 19
States / cities: Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 16 more

Conditions: Healthy Volunteers
Interventions: C16TR, Placebo, Tyvaso®; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Herpes Simplex Type 2
Interventions: HerpV and QS-21, Placebo; Drug
Lead sponsor: Agenus Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 5
States / cities: Portland, Oregon • Houston, Texas • Seattle, Washington

Conditions: HIV Infections
Interventions: AVX101, placebo; Biological · Other
Lead sponsor: AlphaVax, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2005
U.S. locations: 5
States / cities: Baltimore, Maryland • New York, New York • Rochester, New York + 2 more

Conditions: Influenza
Interventions: DNA vaccine, TIV; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 131 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 4
States / cities: Decatur, Georgia • St Louis, Missouri • Cincinnati, Ohio + 1 more

Conditions: Healthy Adult Volunteers
Interventions: NB-1008, Control; Biological · Other
Lead sponsor: NanoBio Corporation; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 199 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Lip Augmentation, Lip
Interventions: RHA 3, Restylane-L; Device
Lead sponsor: Teoxane SA; Industry
Eligibility: 22 Years and older
Enrollment: 202 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Bradenton, Florida

Conditions: Wrinkles
Interventions: Elevess; Device
Lead sponsor: Anika Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 9
States / cities: Los Angeles, California • Boca Raton, Florida • Coral Gables, Florida + 6 more

Conditions: Contact Lens Wearer
Interventions: All participants received Biotrue ONEday lenses with and without an alternate packaging solution (EPG03); Device
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Staphylococcus Aureus
Interventions: NDV-3A, Placebo; Biological
Lead sponsor: NovaDigm Therapeutics, Inc.; Industry
Eligibility: 17 Years to 35 Years · Male only
Enrollment: 382 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Fort Benning, Georgia

Conditions: Cerebrovascular Accident
Interventions: GSK249320A, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetic Macular Edema
Interventions: Macugen (Pegaptanib Sodium); Drug
Lead sponsor: Retina Institute of Hawaii; Other
Eligibility: 18 Years and older
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Posttraumatic Stress Disorder
Interventions: Typhoid Vi Polysaccharide Vaccine, Placebo; Biological
Lead sponsor: University of California, San Francisco; Other
Eligibility: 30 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 2
States / cities: San Francisco, California

Conditions: Lupus Erythematosus, Systemic, Lupus Nephritis
Interventions: abetimus sodium (LJP 394) and/or placebo solution, abetimus sodium (LJP 394), Phosphate-buffered saline; Drug
Lead sponsor: La Jolla Pharmaceutical Company; Industry
Eligibility: 12 Years to 70 Years
Enrollment: 943 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 32
States / cities: Birmingham, Alabama • Los Angeles, California • San Leandro, California + 28 more

Conditions: ASC-US, ASC-H, LSIL
Interventions: PVX-2, Placebo; Biological · Other
Lead sponsor: PapiVax Biotech, Inc.; Other
Eligibility: 25 Years to 70 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 6
States / cities: Port Saint Lucie, Florida • Newark, New Jersey • Fairfield, Ohio + 3 more

Conditions: Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Myelodysplastic Syndrome
Interventions: VCL-CB01, Phosphate-buffered Saline (PBS); Biological · Other
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 22
States / cities: Tucson, Arizona • Duarte, California • Denver, Colorado + 17 more

Conditions: Lyme Borreliosis
Interventions: VLA15, Placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 246 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 5
States / cities: Milford, Connecticut • Stamford, Connecticut • Binghamton, New York + 2 more

Conditions: Osteoarthritis
Interventions: SM04690, Placebo; Drug
Lead sponsor: Biosplice Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 455 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 36
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 32 more

Conditions: Neisseria Meningitidis
Interventions: Trumenba, PENBRAYA; Biological
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 25 Years
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Alzheimer Disease
Interventions: Pepinemab, Placebo; Drug
Lead sponsor: Vaccinex Inc.; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 14
States / cities: San Diego, California • Washington D.C., District of Columbia • Delray Beach, Florida + 11 more

Search by objective public record fields.

Safety and Efficacy Trial of DNA Vaccines to Treat Genital Herpes in Adults

Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection

EP1300 Polyepitope DNA Vaccine Against Plasmodium Falciparum Malaria

Examining the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Crohn's Disease

Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus (SLE) Patients With Active Disease

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of C16TR for Inhalation With Tyvaso® Cohort in Healthy Participants

Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Participants With Recurrent Genital Herpes

Safety of an HIV Vaccine (AVX101) in HIV Uninfected Volunteers in the United States and South Africa

Seasonal Influenza DNA Vaccine Prime With Trivalent Inactivated Vaccine (TIV) Boost Compared to TIV Alone

Safety and Immunogenicity Study of Inactivated Nasal Influenza Vaccine NB-1008

RHA® 3 Versus Restylane-L® for Lip Augmentation

Safety Study of Cosmetic Tissue Augmentation in People of Color

Biotrue ONEday Contact Lenses With EPG03 Packaging Solution Compared to Biotrue ONEday Contact Lenses

Evaluation of NDV-3A Vaccine in Preventing S. Aureus Colonization

Anti-MAG First Administration to Human

A Single-Center Trial of High Frequency Pegaptanib for Rapid Restoration of VEGF Levels in Diabetic Retinal Edema

Inflammation and Threat Sensitivity in PTSD

Study of LJP 394 in Lupus Patients With History of Renal Disease

Phase II Study of Treatment for HPV16+ ASC-US, ASC-H and LSIL

Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)

Alternative Schedule Study For VLA15, a Vaccine Candidate Against Lyme Borreliosis

A Study Evaluating the Safety, Tolerability, and Efficacy of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects

MenB-FHbp or MenACWY-TT/MenB-FHbp Vaccine in MenB-4C Primed Young Adults

SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD)